Prevalence of *BRAF*^{*V600E*} mutation in Asian series of papillary thyroid carcinoma—a contemporary systematic review

Faiza Abdul Rashid[1]^, Jijgee Munkhdelger[2]^, Junya Fukuoka[2,3]^, Andrey Bychkov[2,3]^

[1]Department of Biological Sciences, Faculty of Basic and Applied Sciences, International Islamic University, Islamabad, Pakistan; [2]Department of Pathology, Kameda Medical Center, Kamogawa, Chiba, Japan; [3]Department of Pathology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Contributions: (I) Conception and design: A Bychkov; (II) Administrative support: A Bychkov, J Fukuoka; (III) Provision of study materials or patients: FA Rashid, J Munkhdelger; (IV) Collection and assembly of data: J Munkhdelger, FA Rashid; (V) Data analysis and interpretation: FA Rashid, J Munkhdelger, A Bychkov; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Andrey Bychkov, MD, PhD. Department of Pathology, Kameda Medical Center, 929 Higashi-cho, Kamogawa City, Chiba 296-8602, Japan. Email: bychkov.andrey@kameda.jp.

Abstract: Papillary thyroid carcinoma (PTC), the most common malignancy of the endocrine system, is frequently driven by *BRAF*^{*V600E*} mutation, which was reported in 35–60% cases in Western series. Numerous studies have recently emerged from Asian countries and regions; however sufficient summary is lacking to date. *BRAF* mutation serves as a diagnostic and prognostic tool in thyroid cancer, therefore establishing a rate of *BRAF* on the national scale could be of practical significance. We performed systematic reviews of available literature to investigate the prevalence of *BRAF* mutation in series of PTC from various Asian countries and regions. Out of the total 3,966 reports identified via initial screening, 138 studies encompassing over 40,000 PTCs were included for the final analysis. A vast majority (90.2%) of PTCs with known *BRAF* status were from East Asia, including China, South Korea, and Japan, with *BRAF* mutation rates of 71.2%, 75.5%, and 70.6%, respectively. Less abundant Indian and Saudi Arabian series found 45.6% and 46.3% prevalence of *BRAF*^{*V600E*} in PTC, respectively. Much limited evidence was available from Thailand, Iran, Kazakhstan, Taiwan, Singapore, Indonesia, Hong Kong, Philippines, Vietnam, Iraq, and Myanmar. No relevant publications were found from other highly populated countries, such as Pakistan, Bangladesh, and Malaysia. After grouping by geographic region, we found that the highest rate of *BRAF*^{*V600E*} was reported in the PTC series from East Asia (76.4%). Much lower rate (45–48%) was seen in PTC cohorts from South Asia, Central Asia, and the Middle East while the Southeast Asian series were in between (57%). Further subgroup analysis revealed that studies employing fresh frozen tissue and fine-needle aspirates showed higher rates of *BRAF* compared to those used formalin-fixed paraffin-embedded tissues. We found that the PTC series enrolled patients' cohorts after 2010 demonstrated a higher rate of *BRAF* compared to the earlier series. Finally, pediatric PTCs had lower *BRAF* prevalence compared to the baseline rate for the country. In conclusion, despite considerable among and within countries heterogeneity, the Asian PTC series showed a higher prevalence of *BRAF*^{*V600E*} mutation than that in Western series. Causes of geographic heterogeneity, whether genuine (etiology, genetics) or methodology-related should be further investigated.

Keywords: Asia; *BRAF*^{*V600E*}; China; Japan; Korea; papillary thyroid carcinoma (PTC)

^ ORCID: Faiza Abdul Rashid, 0000-0003-4831-1791; Jijgee Munkhdelger, 0000-0003-3483-2342; Junya Fukuoka, 0000-0002-2496-3050; Andrey Bychkov, 0000-0002-4203-5696.

Introduction

Thyroid carcinoma is the most common endocrine malignancy that represents almost 2.1% of newly diagnosed cancer cases (1). Papillary thyroid carcinoma (PTC) is the most common histological type of differentiated thyroid carcinoma accounting for 75–85% cases, often characterized by low mortality rate and good response to radioiodine therapy (2). The 10-year overall survival rate for differentiated types of thyroid carcinoma is exceeding more than 90% (1).

Different types of thyroid cancer are characterized by different gene alterations. PTC development is closely linked to somatic point mutations in *BRAF* and rearrangements in *RET/PTC1*, *RET/PTC3* and *NTRK1/3* genes (2). Interestingly, driver gene aberrations in well-differentiated thyroid cancer are mutually exclusive. Rearranged during transfection (*RET*) gene encodes a single transmembrane tyrosine kinase receptor (3). *RET/PTC* fusions seem to be important in the early pathogenesis of PTC. These fusions are involved in development of 10–20% of PTC either it is sporadic or radiation-induced PTC (4,5). Other genetic alterations like *RAS* and *PAX/PPARG* are less involved in development of conventional PTC but more often associated with follicular thyroid carcinoma and follicular variant PTC (FVPTC) (2).

B-type Raf kinase (*BRAF*) proto-oncogene is the most common molecular target in PTC. $BRAF^{V600E}$ mutation activates the protein kinase domain of *BRAF* that results in constitutive initiation of mitogen-activated protein kinase pathway, which in turn promotes cell growth and proliferation (5,6). Up to 10–15% of all human cancers are reported to have *BRAF* mutation, with a high prevalence in PTC and melanoma (7). $BRAF^{V600E}$ is detected in about half of PTC cases, and may have higher rates in certain populations and histological types (2,5). In thyroid carcinoma, $BRAF^{V600E}$ mutation has been shown to be associated with high risk clinicopathological characteristics, tumor recurrence, metastasis, and reduced sensitivity to radioiodine therapy (8,9). Recently, $BRAF^{V600E}$ was introduced in the clinical guidelines to aid risk stratification of PTC (10).

Since *BRAF* mutation may serve as a diagnostic and prognostic tool, establishing a rate of *BRAF* on the national scale is of practical significance. Western countries have extensively reported on $BRAF^{V600E}$ mutation rates in the past decade. In particular, the prevalence of $BRAF^{V600E}$ mutation in the USA and Europe was ranging 35–60% (11-13).

Numerous studies have recently emerged from Asian countries and regions; however, these were not sufficiently summarized to date except for showing overall high $BRAF^{V600E}$ mutation prevalence in Asian PTC compared to that in Western series (14,15).

Therefore, we performed a systematic review of available literature to investigate the prevalence of *BRAF* mutation in series of PTC originated from various Asian countries and regions.

Methods

Search strategy

We conducted a search within three electronic databases available for all coauthors (PubMed, Google Scholar, and Scopus). Relevant articles were identified using the following combination of keywords: PTC (or cancer) and BRAF combined with the name of each Asian country. The latter was searched in the authors' affiliation. Transcontinental countries, such as Russia and Turkey were disregarded. An additional manual search was done by screening references within included publications. Furthermore, if the search in the above databases was not successful, relevant local publications were queried from the members of the Asian Working Group in Thyroid Pathology (16). We followed the recommendations of Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement (17).

Data extraction

Results of the search from all sources were imported into EndNote reference manager (Thompson Reuters, New York, NY) and two reviewers (F. R. and J. M.) independently screened the abstracts. Upon mutual agreement on eligibility of the study, both reviewers independently extracted data as per the predefined data collection sheet. The only target of our review was $BRAF^{V600E}$, therefore, other *BRAF* mutations were excluded from the analysis. The following information was extracted: first author, year of publication, name of institution, city, country/region, tissue type used for nucleic acid extraction, technique to detect *BRAF* mutation, total number of PTCs, and number of cases positive for *BRAF*. Therefore, clear indication of all these parameters either in the abstract or full text was qualified as inclusion criteria for our systematic review. Additional information, such as histological type of PTC, age of the cohort (e.g., pediatric), and years where study

Figure 1 The PRISMA flowchart of study selection.

cohort belongs to, was optional but not mandatory. Baseline and clinicopathological characteristics of the patients except specified above were not required. In addition, two reviewers were asked to score and record the quality and risk of bias of the included studies. Any discrepancies during data extraction were resolved after consultation with a supervisor (A. B.) of the study. Studies not qualified as per inclusion criteria were disregarded. More exclusion criteria were as follows: (I) less than 10 cases enrolled; (II) non-primary PTC (regional and distant metastases) only and thyroid tumors other than PTC; (III) experimental and animal studies, (IV) duplicated cohorts. The latter were decided based on the overlapping of the institution name and study cohort in several publications. If potential overlap was found, a study with the largest sample size was selected.

Statistics

Descriptive statistics were calculated with Microsoft Office Excel 2010 (Microsoft, CA, USA). Further statistical analysis was performed with SPSS 23.0 statistical software package (SPSS, Chicago, IL, USA). A χ^2 test with Yates's correction was applied for subgroup analysis. P value of less than 0.05 was considered to be statistically significant.

Results

Out of the total 3,966 studies identified via search in electronic libraries, only 244 met our inclusion criteria and were selected for further evaluation. Finally, after reading abstracts and full texts, 138 studies were qualified as eligible for data extraction. A flow chart of the data selection process is shown in *Figure 1*.

Asian studies classified by country and geographical region

We further separated 3 studies from Japan, China, and Saudi Arabia (18-20) in a subgroup, composed exclusively of pediatric PTCs, and focused on 135 adult or unselected series from Asian countries and regions including 40,371 PTCs. The largest datasets were provided by Japan (*Table 1*), South Korea (*Table 2*), China (*Table 3*), India (*Table 4*), and Saudi Arabia (*Table 5*). Summary of all 135 publications stratified by country and region of origin is shown in *Table 6*.

Nine Japanese studies included 986 PTCs with an average *BRAF* rate 70.6% (*Table 1*). Korean series were more extensive, encompassing 20,599 PTCs in 40 studies with resultant *BRAF* prevalence 75.5% (*Table 2*). The largest number of reports were from China (n=51; 15,509 PTCs), which showed 71.2% *BRAF* rate (*Table 3*). In contrast to the countries above, Indian institutions started to report their findings quite recently, so far providing results on 561 PTCs from 9 centers across the country, averaging 45.6% prevalence of *BRAF*[V600E] mutation (*Table 4*). Five studies from Saudi Arabia (mean *BRAF* rate 46.3%) along with less abundant reports from other Asian countries and regions,

Table 1 Characteristics of included studies from Japan

##	Author	Year	Institution	City	Study cohort	Tissue type	Technique	Total PTC	BRAF+	BRAF rate (%)
1	Kondo T (21)	2007	University of Yamanashi	Yamanashi	n/s	FFPE	Seq	31	13	42
2	Kumagai A (22)	2007	Nagasaki University Hospital	Nagasaki	2003–2006	FNA	PCR-RFLP	14	12	86
3	Takahashi K (23)	2007	Radiation Effects Research Foundation	Hiroshima	2003–2005	FFPE	RFLP	64	38	59
4	Matsuse M (24)	2011	Kuma Hospital	Kobe	n/s	FFPE	Seq	492	388	79
5	Mitsutake N (18)	2015	Fukushima Medical University	Fukushima	2013–2014	Fresh frozen	Seq	67	43	64
6	Xing M (25)	2015	Kanagawa Cancer Center	Yokohama	n/s	Fresh frozen	Seq	49	33	67
7	Nasirden A (26)	2016	Juntendo University Hospital	Tokyo	2009, 2017	FFPE	Seq	144	53	37
8	Vuong HG (27)	2016	Yamanashi Hospital	Yamanashi	2011–2014	FFPE	AS-PCR	67	55	82
9	Oishi N (28)	2017	University of Yamanashi + Kuma Hospital	Yamanashi, Kobe	1991–2013	FFPE	AS-PCR + Seq	172	121	70
10	Bandoh N (29)	2018	Hokuto Hospital	Obihiro	2014–2016	FFPE	Seq	34	27	79

AS-PCR, allele specific-polymerase chain reaction; FFPE, formalin fixed paraffin embedded tissues; FNA, fine needle aspiration; n/s, not specified; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; Seq, sequencing.

Table 2 Characteristics of included studies from South Korea

##	Author	Year	Institution	City	Study cohort	Tissue type	Technique	Total PTC	BRAF+	BRAF rate (%)
1	Kim KH (30)	2005	Eulji University Hospital, Chungnam National University Hospital	Daejeon	2000–2003	FFPE	PCR	79	64	81
2	Kim TY (31)	2005	Asan Medical Center	Seoul	1997–2001	FFPE	PCR	60	31	52
3	Jo YS (32)	2006	Chungnam National University Hospital	Daejeon	2004–2005	FFPE	IHC + Seq	161	102	63
4	Kim TY (33)	2006	Asan Medical Center	Seoul	n/s	FFPE	PCR + Seq	203	149	73
5	Lee JH (34)	2006	Korea University Guro Hospital	Seoul	2000–2003	FFPE	PCR	100	58	58
6	Park SY (35)	2006	Seoul National University Bundang Hospital	Seongnam	2003–2005	FFPE	PCR + Seq	61	53	87
7	Kim SK (36)	2009	Konkuk University Hospital	Seoul	2005–2006	FNA	Pyroseq	101	88	87
8	Kwak JY (37)	2009	Severance Hospital	Seoul	2008	FNA	PCR + Seq	339	213	63

Table 2 (*continued*)

Table 2 (*continued*)

##	Author	Year	Institution	City	Study cohort	Tissue type	Technique	Total PTC	BRAF+	BRAF rate (%)
9	Kim JH (38)	2010	Kosin University College of Medicine	Busan	2007–2009	Fresh frozen	Seq	109	35	32
10	Kim SW (39)	2010	Samsung Medical Center	Seoul	n/s	FNA	PCR + Seq	263	221	84
11	Lee HJ (40)	2010	Asan Medical Center	Seoul	2008	FNA	PCR, Seq, Pyroseq	52	47	90
12	Park YJ (41)	2010	Seoul National University Hospital	Seoul	1983–2004	FFPE	PCR	230	153	67
13	Ahn D (42)	2012	Kyungpook National University Hospital	Daegu	2010	FFPE	multiplex PCR	107	85	79
14	Chang H (43)	2012	Korea University Guro Hospital	Seoul	2008–2009	FNA	Seq + MCA	126	96	76
15	Joo JY (44)	2012	Chungnam National University	Daejeon	2009–2011	FNA	Seq	148	79	53
16	Kim SJ (45)	2012	Seoul National University Hospital	Seoul	2009–2010	FFPE	PCR + Seq	547	381	70
17	Moon WJ (46)	2012	Konkuk University Medical Center	Seoul	2006–2008	FNA	PCR+Seq	164	140	85
18	Choi SY (47)	2013	Dong-A Medical Center	Busan	2011–2012	FFPE	qPCR	101	72	71
19	Jeong D (48)	2013	Soonchunhyang University College of Medicine	Cheonan	n/s	FFPE	qPCR	211	189	90
20	Kang KH (49)	2013	Seoul National University Hospital	Seoul	n/s	Fresh frozen	PCR	46	37	80
21	Lim JY (50)	2013	Severance Hospital	Seoul	2009–2012	FFPE	RFLP + Seq	3130	2313	74
22	Min HS (51)	2013	Seoul National University Hospital	Seoul	2009	FFPE	Seq + IHC	255	179	70
23	Chai YJ (52)	2014	Seoul National University Hospital	Seoul	2009–2013	FFPE	Seq	137	35	26
24	Han SA (53)	2014	Kyung Hee University Hospital	Seoul	2010–2012	FFPE	qPCR	499	353	71
25	Hong AR (54)	2014	Seoul National University Hospital	Seoul	1995–2003, 2009–2012	FFPE	RFLP + Seq	2624	1912	73
26	Jung YY (55)	2015	Chung-Ang University Hospital	Seoul	2011–2012	FFPE	IHC + qPCR, RNA FISH	467	402	86
27	Lee SR (56)	2015	Ajou University	Suwon	2012	FFPE	IHC+ PCR, Seq	163	143	88
28	Na JI (57)	2015	Chonnam National University Hospital	Gwang-ju	2005–2013	FFPE	IHC + qPCR, Seq	104	71	68

Table 2 (*continued*)

Table 2 (*continued*)

##	Author	Year	Institution	City	Study cohort	Tissue type	Technique	Total PTC	BRAF+	BRAF rate (%)
29	Xing M (25)	2015	Ulsan University Hospital	Ulsan	n/s	FFPE	Seq	197	144	73
30	Kim SK (58)	2016	Samsung Medical Center	Seoul	2008–2012	FNA + FFPE	PCR + Seq	3107	2530	81
31	Kim S (59)	2017	Ajou University	Suwon	2009–2013	FFPE	PCR	1503	1171	78
32	Lee SE (60)	2017	Konkuk University Medical Center	Seoul	2010–2014	FNA	Pyroseq	769	625	81
33	Yeo MK (61)	2017	Chungnam National University School of Medicine	Daejeon	2010	FFPE	qPCR	99	88	89
34	Kim H (62)	2018	Pusan National University Hospital	Busan	2011–2012	FFPE	PCR	1411	861	61
35	Kim HJ (63)	2018	Samsung Medical Center	Seoul	2010–2015	FNA	PCR + Seq	215	173	80
36	Kim JK (64)	2018	Seoul National University Hospital	Seoul	2013–2016	FFPE	IHC + Seq	697	627	90
37	Oh HS (65)	2018	Asan Medical Center	Seoul	2011–2013	FFPE	Seq	62	57	92
38	Lee SM (66)	2019	Severance Hospital	Seoul	2011–2012	FNA	qPCR	911	717	79
39	Choden S (67)	2020	St. Mary's Hospital	Seoul	2008–2010	FFPE	IHC + Seq	514	436	85
40	Yoon JH (68)	2020	Severance Hospital	Seoul	2015–2017	FFPE	PCR	527	428	81

AS-PCR, allele specific-polymerase chain reaction; FFPE, formalin fixed paraffin embedded tissues; FISH, fluorescence *in situ* hybridization; FNA, fine needle aspiration; IHC, immunohistochemistry; MCA, melting curve analysis; n/s, not specified; PCR, polymerase chain reaction; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; Pyroseq, pyrosequencing; qPCR, quantitative polymerase chain reaction; Seq, sequencing.

including Iran, Iraq, Kazakhstan, Myanmar, Thailand, Vietnam, Indonesia, Singapore, Taiwan, Hong Kong, and Philippines are shown in *Table 5*. *Figure 2* summarizes *BRAF* prevalence on the color map. We could not find any relevant publications from such large and highly populated Asian countries as Pakistan, Bangladesh, and Malaysia.

After grouping countries by geographic region, we found that the highest rate of $BRAF^{V600E}$ was reported in PTC series from East Asia (76.4%). Much lower rate (45–48%) was seen in PTC cohorts originated from South Asia, Central Asia, and the Middle East while the Southeast Asian series were in between (57%). At the same time, it should be noted that the level of evidence per country demonstrated by the number of studies, number of institutions, and the total sample size was highly heterogeneous (*Figure 3A,B,C*). For instance, 90.2% out of all PTCs with known *BRAF* status were reported from China, South Korea, and Japan—

countries belonging to East Asia. After adjusting the sample size to such variables as the country's population and incidence of thyroid carcinoma, we concluded that the South Korean series provided the best evidence on *BRAF* mutation prevalence at the national level (*Figure 3D*).

Within country heterogeneity

As it could be seen from *Tables 1-5* containing original data, there was a considerable heterogeneity of *BRAF* rate within most of the countries, the best illustrated in Japan (42–86%), South Korea (32–92%), and China (31–87%). Furthermore, such heterogeneity was found even within the same institution. For example, a group from Yamanashi, Japan reported two series of PTC with *BRAF* rate 42% and 82% (21,27). Similar discordances were found in studies from Sichuan, China (31% *vs.* 64%), Daejeon, Korea (53%

Table 3 Characteristics of included studies from China

##	Author	Year	Institution	City	Study cohort	Tissue type	Technique	Total PTC	BRAF+	BRAF rate (%)
1	Gu LQ (69)	2009	Shanghai Jiaotong University School of Medicine + Yueqing People's Hospital	Shanghai, Zhejiang	n/s	FFPE	PCR	123	42	34
2	Guan H (70)	2009	multisite	Shenyang, Shanghai, Binzhou, Heze, Qingdao	1990–2007	FFPE	Seq	1032	639	62
3	Feng L (71)	2011	Dalian Medical University	Dalian	2006–2007	FFPE	IHC	70	42	60
4	Wang W (72)	2012	The First Affiliated Hospital, Zhejiang University School of Medicine	Hangzhou	2006–2008	FFPE	PCR + Seq	208	115	55
5	Xia T (73)	2012	Affiliated Tumor Hospital of Tianjin Medical University	Tianjin	2011	Fresh frozen	PCR + Seq	110	69	63
6	Zheng X (74)	2012	Tianjin Medical University Cancer Institute and Hospital	Tianjin	1995–2000	FFPE	PCR	512	263	51
7	Zhou YL (75)	2012	First Affiliated Hospital of Wenzhou Medical College	Wenzhou	2010–2011	FNA	PCR	100	31	31
8	Gong RX (76)	2013	West China Hospital, Sichuan University	Chengdu	2009–2011	FFPE	PCR	187	119	64
9	Huang Y (77)	2013	The First Affiliated Hospital, Sun Yat-Sen University	Guangzhou	2008–2010	Fresh frozen	PCR	69	33	48
10	Guo HQ (78)	2014	Chinese Academy of Medical Science	Beijing	2010–2011	FNA	PCR	63	41	65
11	He G (79)	2014	West China Hospital, Sichuan University	Sichuan	2009–2011	FFPE	PCR	187	119	64
12	Huang FJ (80)	2014	Shanghai Jiaotong University	Shanghai	2009–2011	Fresh frozen	Seq	214	147	69
13	Liu S (81)	2014	Xian Jiaotong University Health Science Center	Xian	2011–2014	FNA	Pyroseq	132	80	61
14	Liu X (82)	2014	multisite	Shanghai, Shenyang, Qingdao, Heza, Binzhou	n/s	FFPE	PCR	408	250	61
15	Lu H (83)	2014	Chinese Academy of Medical Science	Beijing	2010–2012	FFPE	PCR + Seq	292	190	65
16	Shao H (84)	2014	Heze Municipal Hospital	Shandong	2002–2006	FFPE	Seq	200	133	67

Table 3 (*continued*)

Table 3 (*continued*)

##	Author	Year	Institution	City	Study cohort	Tissue type	Technique	Total PTC	BRAF+	BRAF rate (%)
17	Wei X (85)	2014	Tianjin Cancer Hospital	Tianjin	2011–2013	FFPE	IHC	369	297	80
18	Lu J (86)	2015	Peking Union Medical College Hospital (PUMCH)	Beijing	2013–2014	FFPE	ARMS PCR + qPCR	150	121	81
19	Qiu T (87)	2015	Chinese Academy of Medical Sciences	Beijing	2010–2014	FFPE	IHC + Seq	127	102	80
20	Shi C (88)	2015	Second Affiliated Hospital of Harbin Medical University	Harbin	n/s	FFPE	qPCR	126	87	69
21	Sun J (89)	2015	Peking Union Medical College Hospital (PUMCH)	Beijing	2010–2012	FFPE	IHC + Seq	556	419	75
22	Yang LB (90)	2015	West China Hospital	Sichuan	2013–2014	FFPE	Seq	543	170	31
23	Yu L (91)	2015	Hangzhou First Peoples Hospital	Hangzhou	2012–2013	Fresh frozen	PCR+ Seq	65	40	62
24	Zhao H (92)	2015	Chinese Academy of Medical Sciences	Beijing	2010–2012	FNA	PCR	170	114	67
25	Jin L (93)	2016	Wenzhou Medical University	Wenzhou	2009–2014	FFPE	Seq	653	416	64
26	Sun J (94)	2016	Peking Union Medical College Hospital (PUMCH)	Beijing	2010–2013	FFPE	Seq	455	343	75
27	Wen H (95)	2016	XinJiang Medical University	Urumqi	2007–2011	FFPE	Seq	26	19	73
28	Zhang B (96)	2016	Affiliated Hospital of the Academy of Military Medical Sciences	Beijing	2011–2014	FFPE	ARMS qPCR	120	106	88
29	Zheng L (97)	2016	First Affiliated Hospital of Anhui Medical University	Hefei	2009–2012	FFPE	PCR + Seq	60	40	67
30	Geng J (19)	2017	Beijing Children's Hospital	Beijing	1994–2014	FFPE	qPCR	48	17	35
31	Li Q (98)	2017	Affiliated Cancer Hospital of Zhengzhou University	Zhengzhou	n/s	Fresh frozen	PCR + Seq	34	18	53
32	Zhang Q (99)	2017	Shanghai Tenth People's Hospital of Tongji University School	Shanghai	2015–2016	FFPE	PCR	438	379	87
33	Guan Q (100)	2018	Fudan University Shanghai Cancer Center	Shanghai	2012–2013	FFPE	qPCR + Seq	99	63	64
34	Huang L (101)	2018	Wuhan Puai Hospital	Wuhan	2010–2016	FFPE	qPCR	184	140	76

Table 3 (*continued*)

Table 3 (*continued*)

##	Author	Year	Institution	City	Study cohort	Tissue type	Technique	Total PTC	BRAF+	BRAF rate (%)
35	Liang J (102)	2018	Beijing Cancer Hospital	Beijing	n/s	FFPE	DNA, RNA Seq	355	257	72
36	Liu Z (103)	2018	Shanghai Jiaotong University School of Medicine	Shanghai	2016	Fresh frozen	PCR + Seq	145	81	56
37	Ren H (104)	2018	Chongqing Medical University	Chongqing	2016–2017	Fresh frozen	Seq	342	270	79
38	Zheng B (105)	2018	Guangzhou Kingmed Diagnostics	Guangzhou	2014–2016	FNA	PCR	55	37	67
39	Zhou D (106)	2018	Inner Mongolia Peoples' Hospital	Hohhot	2016–2017	FFPE	PCR	50	37	74
40	Chen B (107)	2019	Hospital of Jiangsu University	Jiangsu	2014–2017	FFPE	Seq	116	70	60
41	Gao J (108)	2020	The First Affiliated Hospital of USTC	Hefei	2017–2018	FFPE	ARMS qPCR	60	39	65
42	Huang M (109)	2019	Xijing Hospital	Xian	2018–2019	FFPE	Seq	483	419	87
43	Ji W (110)	2019	Beijing Shijitan Hospital	Beijing	2012–2015	FFPE	ARMS qPCR	89	67	75
44	Li X (111)	2019	Renji Hospital, Shanghai Jiaotong University	Shanghai	2016–2018	FNA	ARMS PCR	777	674	87
45	Li XJ (112)	2019	Jiangsu Province Hospital	Nanjing	2016–2018	FNA	qPCR	333	304	91
46	Lin ZM (113)	2019	Second Affiliated Hospital, Zhejiang University School of Medicine	Zhejiang	2016–2018	FNA	PCR	1199	791	66
47	Liu Y (114)	2019	Chongqing Medical University	Chongqing	2016–2018	FNA	PCR	207	155	75
48	Shen G (115)	2019	West China Hospital of Sichuan University	Chengdu	2012–2015	FFPE	PCR	236	147	62
49	Wang J (116)	2019	Beijing Hospital	Beijing	2015–2018	FFPE	qPCR	444	384	86
50	Yan C (117)	2019	Xijing Hospital	Shaanxi	2015–2018	FFPE	PCR	2048	1715	84
51	Yang T (118)	2019	West China Hospital, Sichuan University	Chengdu	n/s	FFPE	Seq	326	269	83
52	Zhou C (119)	2019	Liaocheng People's Hospital	Liaocheng	2015–2016	FFPE	qPCR	162	135	83

ARMS-PCR, amplification refractory mutation system-polymerase chain reaction; FFPE, formalin fixed paraffin embedded tissues; FNA, fine needle aspiration; IHC, immunohistochemistry; n/s, not specified; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; Pyroseq, pyrosequencing; qPCR, quantitative polymerase chain reaction; Seq, sequencing.

Table 4 Characteristics of included studies from India

##	Author	Year	Institution	City	Study cohort	Tissue type	Technique	Total PTC	BRAF+	BRAF rate (%)
1	Chakraborty A (120)	2012	Tata Memorial Hospital	Mumbai	2002–2006	Fresh frozen	PCR + Seq	86	46	53
2	Khan MS (121)	2014	Sher-I-Kashmir Institute of Medical Sciences	Srinagar	2010–2012	FFPE	PCR	42	15	36
3	Agarwal S (122)	2016	All India Institute of Medical Sciences	New Delhi	2015–2016	FFPE	Seq	40	19	48
4	Nair CG (123)	2017	Amrita Institute of Medical Sciences	Kochi	2012	FFPE	PCR	59	30	51
5	Ahmad F (124)	2018	Research and Development Division of SRL	Mumbai	n/s	FFPE	PCR + Seq	70	35	50
6	Fonseca D (125)	2018	Basavatarakam Indo American Cancer Hospital	Telangana	2015–2018	FFPE	IHC	23	11	48
7	George N (126)	2018	Sanjay Gandhi Postgraduate Institute	Lucknow	2000–2014	FFPE	PCR	109	56	51
8	Hemalatha R (127)	2018	Christian Medical College	Vellore	n/s	FNA	Seq	53	19	36
9	Krishnamurthy A (128)	2018	Cancer Institute (WIA)	Chennai	2005–2006	FFPE	IHC + qPCR	79	25	32

IHC, immunohistochemistry; FFPE, formalin fixed paraffin embedded tissues; FNA, fine needle aspiration; n/s, not specified; qPCR, quantitative polymerase chain reaction; Seq, sequencing

Table 5 Characteristics of included studies from other Asian countries and regions

Country/ region	##	Author	Year	Institution	City	Study cohort	Tissue type	Technique	Total PTC	BRAF+	BRAF rate (%)
Saudi Arabia	1	Abubaker J (129)	2008	King Faisal Specialist Hospital	Riyadh	1988–2004	FFPE	Seq	296	153	52
	2	Schulten HJ (130)	2012	King Abdulaziz University + King Faisal Specialist Hospital	Jeddah	1995–2011	FFPE	PCR, Seq	213	87	41
	3	Zou M (131)	2014	King Faisal Specialist Hospital	Riyadh	1987–2006	Fresh frozen	Seq	88	42	48
	4	Qasem E (132)	2015	King Faisal Specialist Hospital	Riyadh	2008–2011	FFPE	Seq	243	105	43
	5	Murugan AK (133)	2016	King Faisal Specialist Hospital	Riyadh	n/s	FFPE	Seq	201	95	47
	6	Alzahrani AS (20)	2017	King Faisal Specialist Hospital	Riyadh	1998–2015	FFPE	Seq	79	19	24
Iran	1	Mohammadi-Asl J (134)	2009	Tehran University of Medical Science	Tehran	2007–2008	FFPE	PCR-RFLP	28	20	71
	2	Ranjbari N (135)	2013	Imam Khomeini Hospital	Ahvaz	2000–2010	FFPE	PCR-RFLP	63	49	78
	3	Daliri M (136)	2014	Ghaem Hospital	Mashhad	1999–2014	FFPE	PCR-RFLP	69	28	41

Table 5 (*continued*)

Table 5 (*continued*)

| Country/region	##	Author	Year	Institution	City	Study cohort	Tissue type	Technique	Total PTC	BRAF+	BRAF rate (%)
	4	Zarkesh M (137)	2018	Erfan Hopital + Atiyeh Hospital	Tehran	2015–2016	Fresh frozen	Seq	60	24	40
	5	Ghasemi M (138)	2019	Khalili Hospital	Shiraz	2012–2017	FFPE	PCR-RFLP	79	65	82
Iraq	1	Salih A (139)	2017	Duhok Private Medical Laboratory + Vin Private Medical laboratory	Duhok	2011–2015	FFPE	qPCR	47	12	26
Kazakhstan	1	Kumagai A (22)	2007	Medical Institute of Semipalatinsk	Semipalatinsk	2004–2006	FNA	PCR-RFLP	76	19	25
	2	Tlegenov AS (140)	2018	Kazakh Scientific Research Institute of Oncology and Radiology	Almaty	2016–2017	Fresh frozen	IHC	92	62	67
Myanmar	1	Than MM (141)	2017	Yangon University of Medicine	Yangon	2014–2016	FFPE	PCR	44	10	23
Thailand	1	Choden S (142)	2020	Chulalongkorn University	Bangkok	2007–2017	FFPE	IHC	476	290	61
Vietnam	1	Vuong HG (27)	2016	Cho Ray Hospital	Ho Chi Minh	2011–2014	FFPE	AS-PCR	53	44	83
Indonesia	1	Brahma B (143)	2013	Mangunkusumo Hospital Medical Faculty University	Jakarta	2010–2011	FNA	PCR RFLP	44	17	39
	2	Kristiani E (144)	2016	Siloam Hospitals Lippo Village	Tangerang	n/s	FFPE	IHC	50	17	34
Singapore	1	Yang P (145)	2015	Singapore National University Hospital	Singapore	n/s	FFPE	IHC	49	39	80
	2	Goh X (146)	2019	Singapore National University Hospital	Singapore	2010–2012	FFPE	Seq	75	42	56
Taiwan	1	Liu RT (147)	2005	Chang Gung Memorial Hospital	Kaohsiung	1997–2002	FFPE	Seq	105	49	47
	2	Chang YS (148)	2013	China Medical University Hospital	Taichung	n/s	Fresh frozen	Seq	52	32	62
Hong Kong	1	Lo CC (149)	2004	University of Hong Kong	Hong Kong	2001–2003	FFPE	Seq	34	17	50
	2	Law Y (150)	2009	The Hong Kong Polytechnic University	Hong Kong	n/s	FFPE	PCR RFLP	50	24	48
Philippines	1	Navarro-Locsin CG (151)	2016	St. Luke's Medical Center	Quezon City	2010–2012	FFPE	Seq + qPCR	65	25	38
	2	Espiritu GAM (152)	2019	Makati Medical Center	Makati	2016	FFPE	Seq	17	12	71

AS-PCR, allele specific-polymerase chain reaction; FFPE, formalin fixed paraffin embedded tissues; FNA, fine needle aspiration; IHC, immunohistochemistry; n/s, not specified; PCR-RFLP, polymerase chain reaction-restriction fragment length polymorphism; qPCR, quantitative polymerase chain reaction; Seq, sequencing

Table 6 Summary on BRAF rate in PTC from Asian countries and regions

Region	Country/region	No. of studies	Year of publication	Total PTC*	BRAF-positive	BRAF rate (%)
East Asia	Japan	9	2007–2018	986	696	71
	South Korea	40	2005–2020	20599	15558	76
	China	51	2009–2019	15509	11038	71
	Taiwan	2	2005, 2013	157	81	52
	Hong Kong	2	2004, 2009	84	41	49
South Asia	India	9	2012–2018	561	256	46
Central Asia	Kazakhstan	2	2007, 2018	168	81	48
Middle East	Saudi Arabia	5	2008–2017	1041	482	46
	Iran	5	2008–2017	346	198	57
	Iraq	1	2017	47	12	26
Southeast Asia	Myanmar	1	2017	44	10	23
	Thailand	1	2020	476	290	61
	Vietnam	1	2016	53	44	83
	Indonesia	2	2013, 2016	94	34	36
	Singapore	2	2015, 2019	124	81	65
	The Philippines	2	2016, 2019	82	37	45

*, pediatric cases were excluded if indicated in the original studies (one series from Japan, China, and Saudi Arabia). PTC, papillary thyroid carcinoma.

Figure 2 Prevalence of $BRAF^{V600E}$ mutation in PTC from Asian countries and regions. PTC, papillary thyroid carcinoma.

Figure 3 Summary statistics of publications on *BRAF* mutation by country and region. (A) Total number of studies, (B) total sample size, (C) number of institutions, and (D) ratios of total sample size per annual incidence of thyroid carcinoma and total sample size per population.

vs. 89%), and others (31,44,61,65,79,90).

It is known that the detection rate of *BRAF* may depend on a large variety of factors. As per the data collection form, we were able to assess several of them. First, pediatric PTCs, where indicated, had lower *BRAF* prevalence compared to the baseline rate for the country; however this assumption was based only on a very limited number of studies with pediatric PTCs (18-20,28). Further analysis of factors potentially contributing to the within country heterogeneity was limited to China and South Korea, which had enough studies to be dichotomized by a variable of interest. We found that studies employed fresh frozen tissue and fine-needle aspirates showed a significantly higher rate of *BRAF* compared to those used formalin-fixed paraffin-embedded tissues (78% *vs.* 66% in Chinese series and 79% *vs.* 74% in Korean series; P<0.01). To evaluate a possibility of time trend, we divided studies into those enrolled samples before and after 2010 (only when this was indicated). It was found that the recent PTC series demonstrated a higher rate of *BRAF*—80% *vs.* 58% in Chinese series and 76% *vs.* 72% in Korean series (P<0.01).

Discussion

PTC is the most common malignancy of the endocrine system (153). The prevalence and annual incidence of PTC has approximately triplicated in the last three decades (154). Thyroid carcinoma ranks at the ninth place for incidence rates among all cancers (155). PTC constitutes up to 90% of thyroid carcinoma in contemporary series (156). The estimated age-standardized rate of thyroid cancer incidence in women is 3 times higher than that in men. Thyroid cancer was estimated to be the third most common malignant tumor in women in the USA and the fifth most common in Asia (157). Furthermore, the incidence rate in countries having a high human development index is 4–5 times greater than in those with the low index, while mortality rate does not differ between them (158). This is explained by the early diagnostics, advanced treatment options, and the development of the health care system in general. According to the GLOBOCAN 2018, Asia is the main continent contributing to the epidemiologic profile of thyroid cancer on a worldwide scale (157). For instance, Asia accounted for about 60% of thyroid carcinoma cases in terms of incidence, five-year prevalence, and mortality (157).

While Western opinion is dominating in the contemporary international guidelines on reporting and management of thyroid tumors, a wealth of evidence suggests that there are considerable differences between Western and Asian series of PTC, widely spanning from epidemiology and biology to specific practice patterns and treatment strategies (159-161). $BRAF^{V600E}$ mutation placed on the molecular end of the spectrum is a good example of such disparity. While European and American studies reported 30–60% rate of *BRAF* mutation in PTC, Asian series found it to be much more prevalent (11-15).

It is important that detection of $BRAF^{V600E}$ in PTC may have diagnostic significance in preoperative cytologic aspirates and also in surgical specimens (10,12,43,78,96,101,112). More recently *BRAF* was suggested as an important adjunct in predicting adverse prognosis in PTC, therefore getting wide recognition as a biomarker tailoring postoperative management of PTC patients (10,25). Furthermore, targeting of *BRAF* is considered as a promising strategy for patients with *BRAF*-mutant advanced thyroid cancer. In addition, recent studies found that concomitant *BRAF* and *TERT* promoter mutations in PTC patients were associated with a poor clinical outcome such as tumor aggressiveness and recurrence (162,163). Therefore, establishing a rate of *BRAF* on the regional and even institutional level is of practical significance. For instance, *BRAF* testing for rendering malignancy in preoperative thyroid fine-needle aspirates is much effective in regions with a high prevalence of *BRAF* mutation (39,164).

In this systematic review, we investigated a rate of *BRAF* mutation in a series of more than 40,000 PTCs originated from 16 Asian countries and regions, published in 2004–2020. The highest prevalence of $BRAF^{V600E}$ was reported in East Asian countries (>70%), followed by Southeast Asia (57%), and a region encompassing South Asia, Central Asia, and the Middle East (<50%) (*Figure 2*).

With this largest series to date, we could confirm that PTCs from Asian continent, particularly from East and Southeast Asia are much more saturated with *BRAF* mutation than those from Europe. Studies from Eastern (Poland, Czech Republic), Central (Germany), and Southern Europe (Italy, Spain, Portugal) consistently reported *BRAF* prevalence in PTC below 45% (14,165-172). Series from North (USA) and South America (Brazil) also showed *BRAF* rate lower than in Asia (168,173,174). Although we did not perform extensive search on Western series, existing evidence based on the above studies from leading thyroid cancer centers is sufficient to illustrate a substantial difference between Asian and Western PTC.

In addition to differences among geographic regions, we

found a considerable within-country heterogeneity of *BRAF* rate. Causes of geographic heterogeneity are multifactorial, which could be due to different etiology or study methodology, including selection bias, detection techniques, and many more. There are several etiological factors associated with the development of thyroid carcinoma, of which ionizing radiation has been the well-documented environmental cause of PTC (175). Other factors include genetic predisposition via single nucleotide polymorphisms, hormonal influence, and dietary components, such as iodine and nitrates (24,176,177). The discrepancy identified in the *BRAF^V600E* frequency among different regions of Asia might be due to the variation in the iodine intake. Dietary iodine intake varies in population from as low as 20 μg/d in iodine-deficient areas to as high as 1,000 μg/d in iodine-sufficient areas, where seaweed is rich in iodine, such as Japan and South Korea. Iodine intake is considered as a major risk factor for thyroid tumorigenesis especially in iodine-deficient regions (178). Thyroid follicular cells divide slowly in normal conditions but in the case of iodine deficiency, the proliferation rate of follicular cells increases due to growth of serum TSH level. Excessive proliferation of thyroid follicular cells makes their genome more susceptible to molecular alterations such as *BRAF^V600E* mutation. The overall incidence of histological subtypes of thyroid cancer depends upon level of iodine intake, for instance, follicular thyroid carcinoma is more prevalent in iodine-deficient areas while PTC incidence is greater in high iodine intake areas (179). In China, *BRAF^V600E* mutation is higher in regions where drinking water is rich in iodine compared to mildly deficient iodine intake (70). Interestingly, the most recent studies showed that both low iodine intake and excessive iodine intake served as a significant risk factor for the occurrence of *BRAF* mutations in the thyroid, therefore, may be risk factors for the development of PTC (63,180).

Nevertheless, we do not expect that our *BRAF* prevalence map (*Figure 2*) would match with the iodine status map due to a high complexity and interplay of all the factors that contributed to the variation of *BRAF* rate in different series of PTC. Our data collection protocol did not require extracting additional information about baseline characteristics of the PTC cohorts, such as age, gender, distribution of tumors by histological types, clinical stage, and other important clinicopathological variables. Further systematic review and meta-analysis studies should consider matching PTC series with the major characteristics of enrolled patients, which may help to elucidate certain tumor-specific parameters as a source of heterogeneity.

Apart from the above issues, technical aspects could greatly contribute to heterogeneity of results. We revealed that studies employed fresh frozen tissue and fine-needle aspirates showed significantly higher rates of *BRAF* compared to those used formalin-fixed paraffin-embedded tissues, which could be explained by the poorer DNA quality in the latter specimens. There was a wide variety of molecular methods used across the Asian studies, from a simple gel-based polymerase chain reaction (PCR) and routine Sanger sequencing to highly-sensitive real-time PCR, pyrosequencing, and next-generation sequencing. In addition, mutation-specific immunohistochemistry with VE1 antibody employed as an alternative for genotyping to detect *BRAF^V600E* mutation got increasing adoption in the recent studies.

All the multitude of factors described above could contribute to the geographic heterogeneity of *BRAF* mutation whether within Asia or between Asian and Western series. From the pathologist's standpoint, one of the potential reasons behind the difference is the inter-observer variability in encapsulated follicular lesions between Asian and Western practices (181). Most of Western FVPTCs are classified as benign follicular adenomas or follicular carcinomas in Asia. Follicular variant of PTC is associated with *RAS* driver mutation (2) and sharp increase of this mutation in PTC was documented in US (173) while *RAS*-mutated FVPTCs are rare in Asian series (14), making the *BRAF* mutation rate high in Asian PTC.

This study has several limitations, which are inherently coupled with drawbacks of the original studies, including lack of data about clinicopathological characteristics of patients and histological type of PTC. Despite of the huge amount of data accumulated on *BRAF* mutation prevalence in Asia, more than 90% of PTCs were reported from Japan, South Korea, and China. The evidence from other countries and regions of Asia is very limited (*Figure 3*). Many of the studies were performed on less than 100 samples, which could not be considered sufficient to draw relevant conclusions about the nationwide rate of *BRAF* mutation. Our estimates suggest that 300–400 PTC cases should be enrolled to qualify a well-powered study. However, dealing with a relatively large amount of samples may be challenging in the limited resources settings, which is a case of most Asian countries. Recently we developed and validated a low-cost testing algorithm to estimate the prevalence of *BRAF^V600E* in large cohort studies based on mutation-specific immunostaining applied to small-sized specimens (67,142,182).

Conclusions

Our study found that the highest rate of $BRAF^{V600E}$ was reported in the PTC series from East Asia (76.4%), contributed by South Korea (75.5%), China (71.2%), and Japan (70.6%). Much lower rate (45–48%) based on the limited number of studies was seen in PTC cohorts originated from South Asia, Central Asia, and the Middle East while the Southeast Asian series were in between (57%). Asian series demonstrated considerable among and within countries heterogeneity regarding the prevalence of $BRAF^{V600E}$ mutation in PTC. Pooled Asian series of PTC showed a higher prevalence of $BRAF^{V600E}$ than in Western series. Causes of geographic heterogeneity, whether genuine (etiology, genetics) or methodology-related (selection bias, detection techniques, and more) should be further investigated.

Acknowledgments

Footnote

Provenance and Peer Review: This article was commissioned by the Guest Editor (Kennichi Kakudo) for the series "Asian and Western Practice in Thyroid Pathology: Similarities and Differences" published in *Gland Surgery*. The article was sent for external peer review organized by the Guest Editor and the editorial office.

Peer Review File: Available at http://dx.doi.org/10.21037/gs-20-430

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/gs-20-430). The series "Asian and Western Practice in Thyroid Pathology: Similarities and Differences" was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article

distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Bikas A, Burman KD. Epidemiology of thyroid cancer. In: Luster M, Duntas L, Wartofsky L. editors. The Thyroid and Its Diseases. Cham, Switzerland: Springer, 2019:541-7.
2. Fagin JA, Wells SA Jr. Biologic and Clinical Perspectives on Thyroid Cancer. N Engl J Med 2016;375:1054-67.
3. Romei C, Ciampi R, Elisei R. A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma. Nat Rev Endocrinol 2016;12:192-202.
4. Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer 2014;14:173-86.
5. Xing M. BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. Endocr Rev 2007;28:742-62.
6. Niault TS, Baccarini M. Targets of Raf in tumorigenesis. Carcinogenesis 2010;31:1165-74.
7. Dhomen N, Marais R. New insight into BRAF mutations in cancer. Curr Opin Genet Dev 2007;17:31-9.
8. Kim TH, Park YJ, Lim JA, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer 2012;118:1764-73.
9. Tufano RP, Teixeira GV, Bishop J, et al. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine 2012;91:274-86.
10. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016;26:1-133.
11. Yip L, Nikiforova MN, Carty SE, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery 2009;146:1215-23.
12. Xing M, Clark D, Guan H, et al. BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J

Clin Oncol 2009;27:2977-82.

13. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014;159:676-90.

14. Song YS, Lim JA, Park YJ. Mutation Profile of Well-Differentiated Thyroid Cancer in Asians. Endocrinol Metab (Seoul) 2015;30:252-62.

15. Bychkov A. Prevalence of BRAF(V600E) mutation in Asian patients with thyroid cancer. Malays J Pathol 2017;39:95-6.

16. Bychkov A, Kakudo K, Hong S. Current Practices of Thyroid Fine-Needle Aspiration in Asia: A Missing Voice. J Pathol Transl Med 2017;51:517-20.

17. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.

18. Mitsutake N, Fukushima T, Matsuse M, et al. BRAF(V600E) mutation is highly prevalent in thyroid carcinomas in the young population in Fukushima: a different oncogenic profile from Chernobyl. Sci Rep 2015;5:16976.

19. Geng J, Wang H, Liu Y, et al. Correlation between BRAF (V600E) mutation and clinicopathological features in pediatric papillary thyroid carcinoma. Sci China Life Sci 2017;60:729-38.

20. Alzahrani AS, Murugan AK, Qasem E, et al. Single Point Mutations in Pediatric Differentiated Thyroid Cancer. Thyroid 2017;27:189-96.

21. Kondo T, Nakazawa T, Murata S, et al. Enhanced B-Raf protein expression is independent of V600E mutant status in thyroid carcinomas. Hum Pathol 2007;38:1810-8.

22. Kumagai A, Namba H, Akanov Z, et al. Clinical implications of pre-operative rapid BRAF analysis for papillary thyroid cancer. Endocr J 2007;54:399-405.

23. Takahashi K, Eguchi H, Arihiro K, et al. The presence of BRAF point mutation in adult papillary thyroid carcinomas from atomic bomb survivors correlates with radiation dose. Mol Carcinog 2007;46:242-8.

24. Matsuse M, Takahashi M, Mitsutake N, et al. The FOXE1 and NKX2-1 loci are associated with susceptibility to papillary thyroid carcinoma in the Japanese population. J Med Genet 2011;48:645-8.

25. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol 2015;33:42-50.

26. Nasirden A, Saito T, Fukumura Y, et al. In Japanese patients with papillary thyroid carcinoma, TERT promoter mutation is associated with poor prognosis, in contrast to BRAF (V600E) mutation. Virchows Arch 2016;469:687-96.

27. Vuong HG, Kondo T, Oishi N, et al. Genetic alterations of differentiated thyroid carcinoma in iodine-rich and iodine-deficient countries. Cancer Med 2016;5:1883-9.

28. Oishi N, Kondo T, Nakazawa T, et al. Frequent BRAF (V600E) and Absence of TERT Promoter Mutations Characterize Sporadic Pediatric Papillary Thyroid Carcinomas in Japan. Endocr Pathol 2017;28:103-11.

29. Bandoh N, Akahane T, Goto T, et al. Targeted next-generation sequencing of cancer-related genes in thyroid carcinoma: A single institution's experience. Oncol Lett 2018;16:7278-86.

30. Kim KH, Suh KS, Kang DW, et al. Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis. Pathol Int 2005;55:540-5.

31. Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clinical endocrinology 2005;63:588-93.

32. Jo YS, Li S, Song JH, et al. Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab 2006;91:3667-70.

33. Kim TY, Kim WB, Rhee YS, et al. The BRAF mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clinical endocrinology 2006;65:364-8.

34. Lee JH, Lee ES, Kim YS, et al. BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas. Pathology 2006;38:201-4.

35. Park SY, Park YJ, Lee YJ, et al. Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. Cancer 2006;107:1831-8.

36. Kim SK, Song KH, Lim SD, et al. Clinical and pathological features and the BRAF(V600E) mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis. Thyroid 2009;19:137-41.

37. Kwak JY, Kim EK, Chung WY, et al. Association of BRAFV600E mutation with poor clinical prognostic factors and US features in Korean patients with papillary thyroid microcarcinoma. Radiology 2009;253:854-60.

38. Kim JH, Choi JY. Relationship between BRAF Mutations in Papillary Thyroid Carcinomas and Clinicopathologic Factors. Korean J Endocr Surg 2010;10:147-51.

39. Kim SW, Lee JI, Kim JW, et al. BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for evaluation of thyroid nodule: a large series in a BRAFV600E-prevalent population. J Clin Endocrinol

Metab 2010;95:3693-700.

40. Lee HJ, Choi J, Hwang TS, et al. Detection of BRAF mutations in thyroid nodules by allele-specific PCR using a dual priming oligonucleotide system. Am J Clin Pathol 2010;133:802-8.

41. Park YJ, Kim YA, Lee YJ, et al. Papillary microcarcinoma in comparison with larger papillary thyroid carcinoma in BRAF(V600E) mutation, clinicopathological features, and immunohistochemical findings. Head Neck 2010;32:38-45.

42. Ahn D, Park JS, Sohn JH, et al. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma. Auris Nasus Larynx 2012;39:198-203.

43. Chang H, Lee H, Yoon SO, et al. BRAF(V600E) mutation analysis of liquid-based preparation-processed fine needle aspiration sample improves the diagnostic rate of papillary thyroid carcinoma. Hum Pathol 2012;43:89-95.

44. Joo JY, Park JY, Yoon YH, et al. Prediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective study. J Clin Endocrinol Metab 2012;97:3996-4003.

45. Kim SJ, Lee KE, Myong JP, et al. BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg 2012;36:310-7.

46. Moon WJ, Choi N, Choi JW, et al. BRAF mutation analysis and sonography as adjuncts to fine-needle aspiration cytology of papillary thyroid carcinoma: their relationships and roles. AJR Am J Roentgenol 2012;198:668-74.

47. Choi SY, Park H, Kang MK, et al. The relationship between the BRAF(V600E) mutation in papillary thyroid microcarcinoma and clinicopathologic factors. World J Surg Oncol 2013;11:291.

48. Jeong D, Jeong Y, Park JH, et al. BRAF (V600E) mutation analysis in papillary thyroid carcinomas by peptide nucleic acid clamp real-time PCR. Ann Surg Oncol 2013;20:759-66.

49. Kang KH. Osteopontin expression in papillary thyroid carcinoma and its relationship with the BRAF mutation and tumor characteristics. J Korean Surg Soc 2013;84:9-17.

50. Lim JY, Hong SW, Lee YS, et al. Clinicopathologic implications of the BRAF(V600E) mutation in papillary thyroid cancer: a subgroup analysis of 3130 cases in a single center. Thyroid 2013;23:1423-30.

51. Min HS, Lee C, Jung KC. Correlation of immunohistochemical markers and BRAF mutation status with histological variants of papillary thyroid carcinoma in the Korean population. J Korean Med Sci 2013;28:534-41.

52. Chai YJ, Kim SJ, Kim SC, et al. BRAF mutation in follicular variant of papillary thyroid carcinoma is associated with unfavourable clinicopathological characteristics and malignant features on ultrasonography. Clin Endocrinol (Oxf) 2014;81:432-9.

53. Han SA, Park WS, Jang JH, et al. BRAF mutation may predict higher necessity of postoperative radioactive iodine ablation in papillary thyroid cancer. Ann Surg Treat Res 2014;87:174-9.

54. Hong AR, Lim JA, Kim TH, et al. The Frequency and Clinical Implications of the BRAF(V600E) Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades. Endocrinol Metab (Seoul) 2014;29:505-13.

55. Jung YY, Yoo JH, Park ES, et al. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma. Pathol Res Pract 2015;211:162-70.

56. Lee SR, Yim H, Han JH, et al. VE1 antibody is not highly specific for the BRAF V600E mutation in thyroid cytology categories with the exception of malignant cases. Am J Clin Pathol 2015;143:437-44.

57. Na JI, Kim JH, Kim HJ, et al. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. Virchows Arch 2015;467:155-68.

58. Kim SK, Lee JH, Woo JW, et al. BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma. Head Neck 2016;38 Suppl 1:E1203-9.

59. Kim S, Lee J, Soh EY. The Clinical Significance of the BRAF Mutation in Patients with Papillary Thyroid Cancer. J Endocr Surg 2017;17:175.

60. Lee SE, Hwang TS, Choi YL, et al. Molecular Profiling of Papillary Thyroid Carcinoma in Korea with a High Prevalence of BRAF(V600E) Mutation. Thyroid 2017;27:802-10.

61. Yeo MK, Jung MK, Lee SY, et al. The usefulness of a novel fully automated PCR-based Idylla test for detection of the BRAF V600E mutation in thyroid tissue: comparison with PNA-clamping PCR, real-time PCR and pyrosequencing. J Clin Pathol 2017;70:260-5.

62. Kim H, Kim BH, Kim YK, et al. Prevalence of BRAF(V600E) Mutation in Follicular Variant of Papillary Thyroid Carcinoma and Non-Invasive Follicular Tumor with Papillary-Like Nuclear Features (NIFTP) in a BRAF(V600E) Prevalent Area. J Korean Med Sci

2018;33:e75.

63. Kim HJ, Park HK, Byun DW, et al. Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area. Eur J Nutr 2018;57:809-15.

64. Kim JK, Seong CY, Bae IE, et al. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF(V600E) Mutation in Papillary Thyroid Carcinoma. Ann Surg Oncol 2018;25:1775-81.

65. Oh HS, Kwon H, Park S, et al. Comparison of Immunohistochemistry and Direct Sanger Sequencing for Detection of the BRAF(V600E) Mutation in Thyroid Neoplasm. Endocrinol Metab (Seoul) 2018;33:62-9.

66. Lee SM, Lee CR, Kang SW, et al. Association between BRAFV600E Mutations and Clinicopathological Features of Papillary Thyroid Microcarcinoma (PTMC). J Endocr Surg 2019;19:7.

67. Choden S, Keelawat S, Jung CK, et al. VE1 Immunohistochemistry Improves the Limit of Genotyping for Detecting BRAF(V600E) Mutation in Papillary Thyroid Cancer. Cancers (Basel) 2020;12:596.

68. Yoon JH, Han K, Lee E, et al. Radiomics in predicting mutation status for thyroid cancer: A preliminary study using radiomics features for predicting BRAFV600E mutations in papillary thyroid carcinoma. PloS One 2020;15:e0228968.

69. Gu LQ, Li FY, Zhao L, et al. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma. Thyroid 2009;19:347-54.

70. Guan H, Ji M, Bao R, et al. Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab 2009;94:1612-7.

71. Feng L, Li M, Zhang QP, et al. Utility of BRAF protein overexpression in predicting the metastasis potential of papillary thyroid carcinoma. Oncol Lett 2011;2:59-63.

72. Wang W, Zhao W, Wang H, et al. Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma. Ann Surg Oncol 2012;19:31-6.

73. Xia T, Hu C, Zha J, et al. BRAFV600E Mutation in Papillary Thyroid Carcinoma. Chin Clin Oncol 2012;39:3.

74. Zheng X, Xia T, Lin L, et al. BRAFV600E status and clinical characteristics in solitary and multiple papillary thyroid carcinoma: experience of 512 cases at a clinical center in China. World J Surg Oncol 2012;10:104.

75. Zhou YL, Zhang W, Gao EL, et al. Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma. Asian Pac J Cancer Prev 2012;13:1267-72.

76. Gong RX, Gong YP, Yang J, et al. Efficient detection of the V600E mutation of the BRAF gene in papillary thyroid carcinoma using multiplex allele-specific polymerase chain reaction combined with denaturing high-performance liquid chromatography. Genet Mol Res 2013;12:4990-7.

77. Huang Y, Liao D, Pan L, et al. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation. Eur J Endocrinol 2013;168:675-81.

78. Guo HQ, Zhao H, Zhang ZH, et al. Impact of molecular testing in the diagnosis of thyroid fine needle aspiration cytology: data from mainland China. Dis Markers 2014;2014:912182.

79. He G, Zhao B, Zhang X, et al. Prognostic value of the BRAF V600E mutation in papillary thyroid carcinoma. Oncol Lett 2014;7:439-43.

80. Huang FJ, Fang WY, Ye L, et al. BRAF mutation correlates with recurrent papillary thyroid carcinoma in Chinese patients. Curr Oncol 2014;21:e740-7.

81. Liu S, Zhang B, Zhao Y, et al. Association of BRAFV600E mutation with clinicopathological features of papillary thyroid carcinoma: a study on a Chinese population. Int J Clin Exp Pathol 2014;7:6922-8.

82. Liu X, Qu S, Liu R, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab 2014;99:E1130-6.

83. Lu H, Qiu T, Ying J, et al. [Correlation between BRAF V600E mutation and clinicopathologic features of papillary thyroid carcinoma]. Zhonghua Bing Li Xue Za Zhi 2014;43:794-8.

84. Shao H, Yu X, Wang C, et al. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer. Endocrine 2014;46:285-91.

85. Wei X, Li Y, Zhang S, et al. Prediction of thyroid extracapsular extension with cervical lymph node metastases (ECE-LN) by CEUS and BRAF expression in papillary thyroid carcinoma. Tumour Biol 2014;35:8559-64.

86. Lu J, Gao J, Zhang J, et al. Association between BRAF V600E mutation and regional lymph node metastasis in papillary thyroid carcinoma. Int J Clin Exp Pathol 2015;8:793-9.

87. Qiu T, Lu H, Guo L, et al. Detection of BRAF mutation in Chinese tumor patients using a highly sensitive antibody immunohistochemistry assay. Sci Rep 2015;5:9211.

88. Shi C, Qin H, Ding C, et al. [Association between BRAF

V600E mutation and central lymph node metastasis in patients with papillary thyroid carcinoma]. Zhonghua Zhong Liu Za Zhi 2015;37:123-7.

89. Sun J, Zhang J, Lu J, et al. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma. Int J Clin Exp Pathol 2015;8:15072-8.

90. Yang LB, Sun LY, Jiang Y, et al. The Clinicopathological Features of BRAF Mutated Papillary Thyroid Cancers in Chinese Patients. Int J Endocrinol 2015;2015:642046.

91. Yu L, Ma L, Tu Q, et al. Clinical significance of BRAF V600E mutation in 154 patients with thyroid nodules. Oncol Lett 2015;9:2633-8.

92. Zhao H, Zhang ZH, Zhou B, et al. Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma. Diagn Cytopathol 2015;43:786-90.

93. Jin L, Chen E, Dong S, et al. BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients. Oncotarget 2016;7:18346-55.

94. Sun J, Zhang J, Lu J, et al. BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients. PloS One 2016;11:e0153319.

95. Wen H, Aizezi A, Yasenjiang M, et al. Clinicopathological significance of BRAFV600E mutation in Uyghur Chinese patients with papillary thyroid carcinoma. Int J Clin Exp Pathol 2016;9:200-7.

96. Zhang B, Xu CW, Wu YF, et al. Diagnostic significance of the BRAF V600E mutation in conventional papillary thyroid carcinomas. Int J Clin Exp Med 2016;9:8296-303.

97. Zheng L, Zhao M, Hu X. Clinical significance of HBME-1, Galectin-3, and CK19 expression and the status of BRAF mutation in papillary thyroid carcinoma. Oncol Transl Med 2016;2:174-8.

98. Li Q, Yuan J, Wang Y, et al. Association between the BRAF V600E mutation and ultrasound features of the thyroid in thyroid papillary carcinoma. Oncol Lett 2017;14:1439-44.

99. Zhang Q, Liu BJ, Ren WW, et al. Association between BRAF V600E Mutation and Ultrasound Features in Papillary Thyroid Carcinoma Patients with and without Hashimoto's Thyroiditis. Sci Rep 2017;7:4899.

100. Guan Q, Wang Y, Liao T, et al. Overexpression of trophoblast cell surface antigen 2 is associated with BRAF V600E mutation and aggressive behavior in papillary thyroid cancer. Int J Clin Exp Pathol 2018;11:4130-9.

101. Huang L, Wang X, Huang X, et al. Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma. Oncol Lett 2018;15:4269-77.

102. Liang J, Cai W, Feng D, et al. Genetic landscape of papillary thyroid carcinoma in the Chinese population. J Pathol 2018;244:215-26.

103. Liu Z, Lv T, Xie C, et al. BRAF V600E Gene Mutation Is Associated With Bilateral Malignancy of Papillary Thyroid Cancer. Am J Med Sci 2018;356:130-4.

104. Ren H, Shen Y, Hu D, et al. Co-existence of BRAF(V600E) and TERT promoter mutations in papillary thyroid carcinoma is associated with tumor aggressiveness, but not with lymph node metastasis. Cancer Manag Res 2018;10:1005-13.

105. Zheng B, Zarka MA, Chen C, et al. The largest CAP-certified Chinese reference laboratory experience with the Bethesda system for reporting thyroid cytopathology: correlation with histologic and BRAF data. J Am Soc Cytopathol 2018;7:16-21.

106. Zhou D, Li Z, Bai X. BRAF V600E and RET/PTC Promote the Activity of Nuclear Factor-kappaB, Inflammatory Mediators, and Lymph Node Metastasis in Papillary Thyroid Carcinoma: A Study of 50 Patients in Inner Mongolia. Med Sci Monit 2018;24:6795-808.

107. Chen B, Zhang Z, Wang K, et al. Association of BRAFV600E mutation with ultrasonographic features and clinicopathologic characteristics of papillary thyroid microcarcinoma: A retrospective study of 116 cases. Clin Hemorheol Microcirc 2019;73:545-52.

108. Gao J, Ma XP, Deng FS, et al. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features. Pathol Oncol Res 2020;26:1833-41.

109. Huang M, Yan C, Xiao J, et al. Relevance and clinicopathologic relationship of BRAF V600E, TERT and NRAS mutations for papillary thyroid carcinoma patients in Northwest China. Diagn Pathol 2019;14:74.

110. Ji W, Xie H, Wei B, et al. Relationship between BRAF V600E gene mutation and the clinical and pathologic characteristics of papillary thyroid microcarcinoma. Int J Clin Exp Pathol 2019;12:3492-9.

111. Li X, Li E, Du J, et al. BRAF mutation analysis by ARMS-PCR refines thyroid nodule management. Clinical endocrinology 2019;91:834-41.

112. Li XJ, Mao XD, Chen GF, et al. High BRAFV600E mutation frequency in Chinese patients with papillary thyroid carcinoma increases diagnostic efficacy in cytologically indeterminate thyroid nodules. Medicine

2019;98:e16343.

113. Lin ZM, Yan CX, Song Y, et al. The features of contrast enhanced ultrasound and BRAF V600E in papillary thyroid carcinoma. J Thorac Dis 2019;11:5071-8.

114. Liu Y, He L, Yin G, et al. Association analysis and the clinical significance of BRAF gene mutations and ultrasound features in papillary thyroid carcinoma. Oncol Lett 2019;18:2995-3002.

115. Shen G, Kou Y, Liu B, et al. The BRAFV600E mutation in papillary thyroid microcarcinoma with intermediate-risk to high-risk features: does the mutation have an effect on clinical response to radioiodine therapy? Nucl Med Commun 2019;40:8-13.

116. Wang J, Liu LT, Cui D, et al. [The co-relation of BRAF V600E mutation and factors affecting occurrence and prognosis of papillary thyroid carcinoma]. Zhonghua Bing Li Xue Za Zhi 2019;48:288-92.

117. Yan C, Huang M, Li X, et al. Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma. Endocr Connect 2019;8:988-96.

118. Yang T, Chen C, Pan NF, et al. [BRAF V600E Mutation and TERT Promoter Mutation in Papillary Thyroid Carcinomas and Their Association with Clinicopathological Characteristics]. Sichuan Da Xue Xue Bao Yi Xue Ban 2019;50:919-24.

119. Zhou C, Li J, Wang Y, et al. Association of BRAF gene and TSHR with cervical lymph node metastasis of papillary thyroid microcarcinoma. Oncol Lett 2019;17:183-94.

120. Chakraborty A, Narkar A, Mukhopadhyaya R, et al. BRAF V600E mutation in papillary thyroid carcinoma: significant association with node metastases and extra thyroidal invasion. Endocr Pathol 2012;23:83-93.

121. Khan MS, Pandith AA, Azad N, et al. Impact of molecular alterations of BRAF in the pathogenesis of thyroid cancer. Mutagenesis 2014;29:131-7.

122. Agarwal S, Sharma MC, Karak AK, et al. BRAF mutation may predict higher risk of incomplete response to radioactive iodine ablation in papillary thyroid carcinoma. Indian J Endocrinol Metab 2016;21:1.

123. Nair CG, Babu M, Biswas L, et al. Lack of Association of B-type Raf Kinase V600E Mutation with High-risk Tumor Features and Adverse Outcome in Conventional and Follicular Variants of Papillary Thyroid Carcinoma. Indian J Endocrinol Metab 2017;21:329-33.

124. Ahmad F, Nathani R, Venkat J, et al. Molecular evaluation of BRAF gene mutation in thyroid tumors: Significant association with papillary tumors and extra thyroidal extension indicating its role as a biomarker of

aggressive disease. Experimental and molecular pathology 2018;105:380-6.

125. Fonseca D, Murthy SS, Tagore R, et al. BRAF status in the variants of papillary thyroid carcinoma. Int J Head Neck Pathol 2018;1:41-7.

126. George N, Agarwal A, Kumari N, et al. Mutational Profile of Papillary Thyroid Carcinoma in an Endemic Goiter Region of North India. Indian J Endocrinol Metab 2018;22:505-10.

127. Hemalatha R, Pai R, Manipadam MT, et al. Presurgical Screening of Fine Needle Aspirates from Thyroid Nodules for BRAF Mutations: A Prospective Single Center Experience. Indian J Endocrinol Metab 2018;22:785-92.

128. Krishnamurthy A, Ramshankar V, Murhekar K, et al. Clinical utility of immunohistochemistry using the novel anti-BRAF V600E antibody (clone RM8) for detection of the BRAF V600E mutant protein in papillary thyroid cancers. Int J Mol Immuno Oncol 2018;3:28.

129. Abubaker J, Jehan Z, Bavi P, et al. Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population. J Clin Endocrinol Metab 2008;93:611-8.

130. Schulten HJ, Salama S, Al-Mansouri Z, et al. BRAF mutations in thyroid tumors from an ethnically diverse group. Hered Cancer Clin Pract 2012;10:10.

131. Zou M, Baitei EY, Alzahrani AS, et al. Concomitant RAS, RET/PTC, or BRAF mutations in advanced stage of papillary thyroid carcinoma. Thyroid 2014;24:1256-66.

132. Qasem E, Murugan AK, Al-Hindi H, et al. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Endocr Relat Cancer 2015;22:901-8.

133. Murugan AK, Qasem E, Al-Hindi H, et al. Classical V600E and other non-hotspot BRAF mutations in adult differentiated thyroid cancer. J Transl Med 2016;14:204.

134. Mohammadi-Asl J, Larijani B, Khorgami Z, et al. Prevalance of BRAFV600E Mutation in Iranian Patients with Papillary Thyroid Carcinoma: A Single-Center Study. J Appl Sci 2009;9:3593-7.

135. Ranjbari N, Almasi S, Mohammadi-Asl J, et al. BRAF mutations in Iranian patients with papillary thyroid carcinoma. Asian Pac J Cancer Prev 2013;14:2521-3.

136. Daliri M, Abbaszadegan MR, Bahar MM, et al. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study. Endocr Res 2014;39:189-93.

137. Zarkesh M, Zadeh-Vakili A, Azizi F, et al. The Association of BRAF V600E Mutation With Tissue Inhibitor of

Metalloproteinase-3 Expression and Clinicopathological Features in Papillary Thyroid Cancer. Int J Endocrinol Metab 2018;16:e56120.

138. Ghasemi M, Behbahani AB, Farhadi A, et al. Prevalence of BRAFV600E Mutation and Human Parvovirus B19 Infection in Thyroid Cancer. Shiraz E Med J 2019. [Epub ahead of print].

139. Salih A, Naqshabandi M, Hassan N, et al. Braf Gene Mutation and CD56 Immunoexpression in Papillary Thyroid Carcinoma in Duhok-Iraq. Journal of Sulaimani Medical College 2017. doi: 10.17656/jsmc.10126.

140. Tlegenov AS, Abylaiuly Z, Adilbay DG, et al. Prevalence of Mutant BRAFV600E in the Papillary Thyroid Carcinoma in Patients from Kazakhstan and Its Correlation with Clinical-Morphological Tumor Characteristic. Medical News of North Caucasus 2018. doi: 10.14300/mnnc.2018.13079.

141. Than MM. BRAF(V600E) Mutation in Papillary Thyroid Carcinoma. Yangon, Republic of the Union of Myanmar.: University of Medicine. 2017.

142. Choden S, Keelawat S, Jung CK, et al. An affordable immunohistochemical approach to estimate the prevalence of BRAFV600E in large cohort studies—establishing the baseline rate of BRAF mutation in an institutional series of papillary thyroid carcinoma from Thailand. Gland Surg 2020. [Epub ahead of print].

143. Brahma B, Yulian ED, Ramli M, et al. Surgical perspective of T1799A BRAF mutation diagnostic value in papillary thyroid carcinoma. Asian Pac J Cancer Prev 2013;14:31-7.

144. Kristiani E, Makes B, Hardjolukito A, et al. BRAF V600E immunoexpression in papillary thyroid carcinoma and its association with prognostic factors and histopathologic variant. Virchows Arch 2016;469:S76.

145. Yang P, Lum H, Quek J, et al. Braf Immunohistochemistry Score Predicts BRAF V600E Mutational Status in Classical Papillary Thyroid Cancer. Thyroid 2015;25 Suppl 1:A356-83.

146. Goh X, Lum J, Yang SP, et al. BRAF mutation in papillary thyroid cancer-Prevalence and clinical correlation in a South-East Asian cohort. Clin Otolaryngol 2019;44:114-23.

147. Liu RT, Chen YJ, Chou FF, et al. No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clinical endocrinology 2005;63:461-6.

148. Chang YS, Lin IL, Yeh KT, et al. Rapid detection of K-, N-, H-RAS, and BRAF hotspot mutations in thyroid cancer using the multiplex primer extension. Clin Biochem 2013;46:1572-7.

149. Lo CC. A Study of BRAF and RAS genes in Papillary Thyroid. Hong Kong: University of Hong Kong, 2004.

150. Law Y. Analysis of BRAF V600E Mutation in Thyroid Aspirates for Establishing a Pre-operative Diagnosis of Thyroid Tumours. Hong Kong: Hong Kong Polytechnic University, 2009.

151. Navarro-Locsin CG, Chang AM, Daroy ML, et al. Clinical and histopathological profile of BRAF V600E mutation in conventional papillary thyroid carcinoma in a Filipino population. Malays J Pathol 2016;38:141-8.

152. Espiritu GAM, Malana JT, Dumasis A, et al. High Preponderance of BRAF V600E Mutation in Papillary Thyroid Carcinoma Among Filipinos: A Clinicopathologic Study. J Glob Oncol 2019;5:1-6.

153. Mao Y, Xing M. Recent incidences and differential trends of thyroid cancer in the USA. Endocr Relat Cancer 2016;23:313-22.

154. Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013;2013:965212.

155. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.

156. Bychkov A, Jung CK, Liu Z, et al. Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features in Asian Practice: Perspectives for Surgical Pathology and Cytopathology. Endocr Pathol 2018;29:276-88.

157. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 2019;144:1941-53.

158. Simard EP, Ward EM, Siegel R, et al. Cancers with increasing incidence trends in the United States: 1999 through 2008. CA Cancer J Clin 2012;62:118-28.

159. Kakudo K, Higuchi M, Hirokawa M, et al. Thyroid FNA cytology in Asian practice-Active surveillance for indeterminate thyroid nodules reduces overtreatment of thyroid carcinomas. Cytopathology 2017;28:455-66.

160. Bychkov A, Hirokawa M, Jung CK, et al. Low Rate of Noninvasive Follicular Thyroid Neoplasm with Papillary-Like Nuclear Features in Asian Practice. Thyroid 2017;27:983-4.

161. Kakudo K, Bychkov A, Abelardo A, et al. Malpractice Climate Is a Key Difference in Thyroid Pathology Practice Between North America and the Rest of the World. Arch Pathol Lab Med 2019;143:1171.

162. Vuong HG, Altibi AMA, Duong UNP, et al. Prognostic implication of BRAF and TERT promoter mutation combination in papillary thyroid carcinoma-A meta-analysis. Clinical endocrinology 2017;87:411-7.

163. Song YS, Yoo SK, Kim HH, et al. Interaction of BRAF-induced ETS factors with mutant TERT promoter in papillary thyroid cancer. Endocr Relat Cancer 2019;26:629-41.

164. Kleiman DA, Sporn MJ, Beninato T, et al. Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules: a prospective case series of 960 patients. Cancer 2013;119:1495-502.

165. Melo M, Gaspar da Rocha A, Batista R, et al. TERT, BRAF, and NRAS in Primary Thyroid Cancer and Metastatic Disease. J Clin Endocrinol Metab 2017;102:1898-907.

166. Xing M. BRAF V600E mutation and papillary thyroid cancer. JAMA 2013;310:535.

167. Sykorova V, Dvorakova S, Ryska A, et al. BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic. J Endocrinol Invest 2010;33:318-24.

168. Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA 2013;309:1493-501.

169. Musholt TJ, Fottner C, Weber MM, et al. Detection of papillary thyroid carcinoma by analysis of BRAF and RET/PTC1 mutations in fine-needle aspiration biopsies of thyroid nodules. World J Surg 2010;34:2595-603.

170. Lupi C, Giannini R, Ugolini C, et al. Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab 2007;92:4085-90.

171. Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab 2010;95:4197-205.

172. Riesco-Eizaguirre G, Gutierrez-Martinez P, Garcia-Cabezas MA, et al. The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr Relat Cancer 2006;13:257-69.

173. Jung CK, Little MP, Lubin JH, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 2014;99:E276-85.

174. Oler G, Cerutti JM. High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer 2009;115:972-80.

175. Iglesias ML, Schmidt A, Ghuzlan AA, et al. Radiation exposure and thyroid cancer: a review. Arch Endocrinol Metab 2017;61:180-7.

176. Rogounovitch TI, Bychkov A, Takahashi M, et al. The common genetic variant rs944289 on chromosome 14q13.3 associates with risk of both malignant and benign thyroid tumors in the Japanese population. Thyroid 2015;25:333-40.

177. Orim F, Bychkov A, Shimamura M, et al. Thyrotropin signaling confers more aggressive features with higher genomic instability on BRAF(V600E)-induced thyroid tumors in a mouse model. Thyroid 2014;24:502-10.

178. Harach HR, Ceballos GA. Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model. Endocr Pathol 2008;19:209-20.

179. Zimmermann MB, Boelaert K. Iodine deficiency and thyroid disorders. Lancet Diabetes Endocrinol 2015;3:286-95.

180. Lee JH, Song RY, Yi JW, et al. Case-Control Study of Papillary Thyroid Carcinoma on Urinary and Dietary Iodine Status in South Korea. World J Surg 2018;42:1424-31.

181. Hirokawa M, Carney JA, Goellner JR, et al. Observer variation of encapsulated follicular lesions of the thyroid gland. Am J Surg Pathol 2002;26:1508-14.

182. Bychkov A, Jain D. Multiple sections per slide for immunohistochemistry: A cost-effective alternative for research in resource-limited settings. Anal Quant Cytol Histol 2018;40:211-2.